(Reuters) -(To receive the full newsletter in your inbox for free sign up here) A large study adds to evidence that the main ingredient in Novo Nordisk's injectable GLP-1 drug for type 2 diabetes ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.

The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the ...

Danish drugmaker Novo Nordisk said several hundred counterfeit units of its diabetes drug Ozempic were being distributed in ...

The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart disease.

An estimated 830 million people have diabetes, with type 2 being the most common. Pharmaceutical giant Novo Nordisk (NYSE: NVO) built its business on insulin and has emerged as a leading innovator ...

An estimated 830 million people have diabetes, with type 2 being the most common. Should investors buy Novo Nordisk stock? Here is what to know. Patients can't get enough of Novo Nordisk's GLP-1 ...

Novo Nordisk agreed to pay up to $2 billion for the rights to a developmental weight-loss and obesity drug from Chinese ...

The European Commission has granted marketing authorisation for Novo Nordisk’s adult diabetes treatments Tresiba and Ryzodeg. The approval covers all 27 European Union member states. Tresiba ...

Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL trial finds Rybelsus lowers cardiovascular risk by 14%.

The dive in Novo Nordisk's stock price in March 2025 was primarily due to a pipeline setback. Earlier this month, the company reported achieving a 15.7% weight loss in obese and type 2 diabetes ...